Gm Advisory Group, Inc. Akebia Therapeutics, Inc. Transaction History

Gm Advisory Group, Inc.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$2.83 - $4.2 $226,400 - $336,000	-80,000 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$2.22 - $3.78 $88,800 - $151,200	40,000 Added 100.0%	80,000 $224,000
Q3 2020 Nov 12, 2020	BUY	$2.39 - $13.08 $95,600 - $523,200	40,000 New	40,000 $100,000

127

56.7M

937K

743K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $175M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of Gm Advisory Group, Inc., based on Form 13F filings with the SEC.

Stay updated on Gm Advisory Group, Inc. with notifications on news.